Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 5/20 | 0.33 |
| ▸ | TNKS | O95271 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767344 | 0.86 | RXRA (0.52) | RXRARXRBRXRGGRIN2BCYP4F2 | |
| SCHEMBL767362 | 0.86 | RXRA (0.53) | RXRARXRBRXRGGRIN2BCYP4F2 | |
| SCHEMBL767203 | 0.86 | RXRA (0.56) | RXRARXRBRXRGGRIN2BCYP4F2 | |
| SCHEMBL767127 | 0.86 | RXRA (0.51) | RXRARXRBRXRGGRIN2BCYP4F2 | |
| SCHEMBL767413 | 0.85 | RXRA (0.53) | RXRARXRBRXRGGRIN2BCYP4F2 | |
| SCHEMBL767482 | 0.85 | RXRA (0.53) | RXRARXRBRXRGGRIN2BCYP4F2 | |
| SCHEMBL767409 | 0.84 | RXRA (0.52) | RXRARXRBRXRGGRIN2BCYP4F2 | |
| SCHEMBL767602 | 0.84 | RXRA (0.52) | RXRARXRBRXRGGRIN2BCYP4F2 | |
| SCHEMBL767635 | 0.84 | RXRA (0.54) | RXRARXRBRXRGGRIN2BCYP4F2 | |
| SCHEMBL767359 | 0.83 | RXRA (0.51) | RXRARXRBRXRGGRIN2BCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-08-13 | — | — | US | disclosed |
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-08-13 | — | — | US | disclosed |
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | RXRA 544/4885RXRB 499/4885RXRG 673/4885 |
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | BRCA1, ESR2, ESR1 | RXRA 283/4885RXRB 261/4885RXRG 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.